The Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Drainage

INCLUSION CRITERIA Preoperative: * Female gender * Age ≥ 18 years * Breast cancer N+ * Conservative Surgery: Lumpectomy or Quadrantectomy * Berg levels 1-2 axillary lymphadenectomy Intraoperative: * Axillary incision separated from the incision for the breast lesion * Placement of a closed low pressure suction drain in the axillary fossa * Hemostasis and lymphostasis using clips, electrocautery, electric scalpel or bipolar coagulation Postoperative: \- Patients with ≥ 10 axillary nodes removed EXCLUSION CRITERIA Preoperative: * Mastectomy * Previous radiation therapy * Previous axillary emptying * Liver pathology * Diabetic decompensation: defined as any episode that has required medical attention in an emergency service or hospital admission; and also that which has required a modification of the patient's drugs, or an increase of more than 20% of the total daily dose. * Known allergies to any component of Hemopatch (proteins of bovine origin or PEG) * Psychiatric disorder that conditions the non-understanding of the questionnaire, or incapacitation of the patient to understand it * Simultaneous participation in another clinical study * PCR positive for SARS-CoV-2 Intraoperative: * Level 3 axillary dissection (severe axillary involvement) * Unexpected surgical contraindication * Hemostasis and lymphostasis: ultrasonic techniques or other advanced energy techniques are excluded. * Use of fibrin sealants (eg: Tisseel, Artiss, Tachosil), cyanoacrylate type adhesives (eg: Glubran-2) or other types of products (oxidized cellulose format, powders or gelatin sheets or collagen).